Azitra Inc (AZTR) AI Stock Analysis

• Market Cap: $3.78M
• Dividend Yield: N/A
• Average Volume (3M): 5.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -100.00%
• EPS Growth: 95.01%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.20
• Shares Outstanding: 5,404,968
• 10 Day Avg. Volume: 152,793
• 30 Day Avg. Volume: 5,373,574
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 0.51
• Enterprise Value/Gross Profit: 0.51
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $0.50
• Price Target Upside: -28.57% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Azitra Inc's overall stock score is primarily driven by weak financial performance and unfavorable technical indicators. While corporate events reflect positive strategic developments, they are insufficient to offset significant financial concerns and poor valuation metrics.

Positive Factors

Innovative Product Development

The initiation of Phase 1/2 trials for ATR04-484, with FDA Fast Track designation, underscores Azitra's innovative approach in addressing unmet dermatological needs, potentially leading to new revenue streams and market expansion.

Strategic Capital Structure

Increasing authorized shares enhances Azitra's capital structure, providing flexibility for future financing and strategic investments, which can support long-term growth initiatives and operational expansion.

Positive Clinical Trial Results

Positive Phase 1b trial results for ATR12-351 indicate progress in Azitra's pipeline, enhancing its potential to deliver novel treatments for rare skin conditions, which could drive future revenue and market differentiation.

Negative Factors

High Operating Losses

Persistent high operating losses indicate ongoing financial challenges, which may strain resources and necessitate external funding, potentially impacting Azitra's ability to sustain long-term operations without significant revenue growth.

Negative Cash Flows

Significant negative cash flows highlight liquidity constraints, limiting Azitra's operational flexibility and ability to invest in growth initiatives, potentially affecting its long-term financial health and sustainability.

Significant Liabilities

High liabilities present financial risk, potentially impacting Azitra's ability to manage debt and invest in future growth, especially if revenue growth does not keep pace with financial obligations.

Azitra Inc Business Overview & Revenue Model

Company Description

Azitra Inc (AZTR) is a biotechnology company that operates in the healthcare sector. The company is focused on developing innovative therapies for dermatological conditions by leveraging its proprietary microbiome technology platform. Azitra's core products aim to address a range of skin diseases and conditions by harnessing the natural properties of beneficial bacteria.

How the Company Makes Money

Azitra Inc makes money through the development and commercialization of its microbiome-based dermatological therapies. The company generates revenue through partnerships and collaborations with other pharmaceutical and biotechnology companies, who may license Azitra's technology for further development and commercialization. Additionally, Azitra may earn income from milestone payments and royalties from successful product launches. The company's revenue model is bolstered by research grants and funding to advance its scientific research and product development efforts.

Azitra Inc Financial Statement Overview

Summary

Azitra Inc shows strong revenue growth but suffers from high net and operating losses, negative cash flows, and significant liabilities. Despite improved equity, these financial vulnerabilities weigh heavily on the overall financial performance score.

Income Statement

Azitra Inc reported significant revenue growth from $686,000 in 2023 to $7,500,000 in 2024, indicating a positive trajectory in revenue generation. However, the company suffers from extremely high net and operating losses, demonstrated by negative EBIT and EBITDA figures. The net profit margin remains negative due to substantial operational expenses surpassing revenue gains.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity of $5,698,298,000 in 2024, reflecting a positive turnaround from negative equity in previous years. The debt-to-equity ratio is low, indicating prudent financial leverage. However, considerable liabilities could pose risks if revenue growth does not continue.

Cash Flow

Negative operating cash flows of -$10,183,740,000 in 2024 highlight cash constraints, limiting operational flexibility. Free cash flow remains deeply negative, though slight improvement is seen from the previous period. The lack of positive cash flows raises concerns about the company's ability to fund operations without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.49M	7.50M	686.00K	284.00K	110.00K
Gross Profit	7.39M	7.50M	260.45K	-121.98K	25.23K
EBITDA	-3.11B	-8.50M	-10.67M	-10.02M	-8.79M
Net Income	-3.07B	-8.97M	-11.28M	-10.68M	-8.94M
Balance Sheet
Total Assets	3.96B	7.36M	5.12M	7.17M	10.20M
Cash, Cash Equivalents and Short-Term Investments	1.05B	4.55M	1.80M	3.49M	8.04M
Total Debt	577.86M	555.51K	885.95K	7.73M	992.02K
Total Liabilities	1.73B	1.66M	2.20M	43.43M	35.97M
Stockholders Equity	2.23B	5.70M	2.91M	-36.26M	-25.77M
Cash Flow
Free Cash Flow	-3.08B	-10.23M	-7.68M	-8.51M	-8.52M
Operating Cash Flow	-3.08B	-10.22M	-7.36M	-8.35M	-8.07M
Investing Cash Flow	-21.95M	-379.25K	-318.26K	-336.76K	-652.27K
Financing Cash Flow	1.76B	13.36M	5.98M	4.13M	992.86K

Azitra Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 1.01, and below the 200-day MA of 1.85, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 32.49 is Neutral, neither overbought nor oversold. The STOCH value of 18.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.

Azitra Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDRX	45 Neutral	$3.93M	-0.10	―	―	-100.00%	86.75%
GRI	45 Neutral	$4.90M	-0.08	―	―	―	98.45%
AZTR	44 Neutral	$3.78M	―	-473.31%	―	-100.00%	95.01%
SLRX	30 Underperform	$3.57M	-0.08	―	―	―	74.27%
PCSA	29 Underperform	$10.72M	-0.09	―	―	―	57.99%
PTIX	27 Underperform	$8.22M	-0.36	―	―	―	38.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Azitra Inc Corporate Events

Azitra Inc Modifies Agreement with Alumni Capital

On August 26, 2025, Azitra, Inc. entered into a Modification Agreement with Alumni Capital LP to amend terms of a previous Purchase Agreement. This allows Azitra to sell up to $20 million of its common stock to Alumni Capital, with specific options for determining the purchase price. The agreement provides flexibility in stock sales, potentially impacting Azitra’s financial strategy and market operations.

Azitra Inc Announces Reverse Stock Split Implementation

On August 20, 2025, Azitra, Inc. filed a certificate of amendment to implement a 1-for-6.66 reverse stock split of its common stock, following approval by its stockholders earlier in February 2025. This reverse stock split will take effect on August 21, 2025, and the company’s stock will begin trading on a split-adjusted basis on the NYSE American. The reverse stock split aims to consolidate every 6.66 shares into one, without affecting the par value or other terms of the common stock, and stockholders entitled to fractional shares will receive cash payments instead.

Azitra Inc Approves Increase in Common Stock Shares

On July 3, 2025, Azitra, Inc. held a reconvened annual meeting of stockholders where they approved an amendment to the company’s Certificate of Incorporation to increase the authorized common stock shares from 100 million to 200 million. This decision, which was initially proposed on June 23, 2025, and required additional time for voting, reflects a strategic move to potentially enhance the company’s capital structure and market positioning.

Azitra Inc Approves Director Elections and Share Issuance

On June 23, 2025, Azitra, Inc. held its annual meeting of stockholders where a quorum was achieved with proxies from over one-third of the shares. The meeting resulted in the approval of the election of four directors and the ratification of Grassi & Co. as the independent accounting firm for 2025. Additionally, stockholders approved the issuance of more than 19.99% of the company’s shares under a purchase agreement with Alumni Capital LP. However, voting on a proposal to increase the authorized shares was adjourned to July 3, 2025, to allow more time for stockholder participation.

Azitra Inc Plans Stock Increase at Annual Meeting

Azitra, Inc. announced updates to its 2025 Annual Meeting of Stockholders, scheduled for June 23, 2025. The company aims to amend its Certificate of Incorporation to increase its authorized common stock from 100 million to 200 million shares, following changes in the Delaware General Corporation Law affecting voting standards. This move reflects Azitra’s strategic positioning to potentially expand its market presence and operational capacity.

Azitra Inc Announces Positive Phase 1b Trial Results

On June 17, 2025, Azitra, Inc. announced promising safety data from its Phase 1b clinical trial for ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial, which is halfway enrolled, showed that ATR12-351 was generally safe and well-tolerated, with only mild to moderate application site reactions reported. This milestone marks significant progress in Azitra’s mission to bring ATR12-351 to market, potentially offering a life-changing treatment for those affected by this rare skin condition.